Differential effects of bexarotene on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell lines

References

• Gura T. How TRAIL kills cancer cells, but not normal cells (comment). Science 1997; 277: 768
   PubMed Web of Science ®Google Scholar
• Wiley S R, Schooley K, Smolak P J, Din W S, Huang C P, Nicholl J K, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673–682
   PubMed Web of Science ®Google Scholar
• Zhang X D, Nguyen T, Thomas W D, Sanders J E, Hersey P. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 2000; 482: 193–199
   PubMed Web of Science ®Google Scholar
• Snell V, Clodi K, Zhao S, Goodwin R, Thomas E K, Morris S W, et al. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol 1997; 99: 618–624
   PubMed Web of Science ®Google Scholar
• Secchiero P, Melloni E, Heikinheimo M, Mannisto S, Di Pietro R, Iacone A, et al. TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood 2004; 103: 517–522
   PubMed Web of Science ®Google Scholar
• Clodi K, Wimmer D, Li Y, Goodwin R, Jaeger U, Mann G, et al. Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells. Br J Haematol 2000; 111: 580–586
   PubMed Web of Science ®Google Scholar
• MacFarlane M, Ahmad M, Srinivasula S M, Fernandes-Alnemri T, Cohen G M, Alnemri E S. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997; 272: 25417–25420
   PubMed Web of Science ®Google Scholar
• Barnhart B C, Alappat E C, Peter M E. The CD95 type I/type II model (Review). Semin Immunol 2003; 15: 185–193
   PubMed Web of Science ®Google Scholar
• Scaffidi C, Schmitz I, Zha J, Korsmeyer S J, Krammer P H, Peter M E. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem 1999; 274: 22532–22538
   PubMed Web of Science ®Google Scholar
• Roy S, Nicholson D W. Cross-talk in cell death signaling (review). J Exp Med 2000; 192: F21–F25
   Web of Science ®Google Scholar
• Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli K J, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17: 1675–1687
   PubMed Web of Science ®Google Scholar
• Walczak H, Krammer P H. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems (review). Exp Cell Res 2000; 256: 58–66
   PubMed Web of Science ®Google Scholar
• Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190–195
   PubMed Web of Science ®Google Scholar
• MacFarlane M, Harper N, Snowden R T, Dyer M J, Barnett G A, Pringle J H, et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 2002; 21: 6809–6818
   PubMed Web of Science ®Google Scholar
• Grotzer M A, Eggert A, Zuzak T J, Janss A J, Marwaha S, Wiewrodt B R, et al. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 2000; 19: 4604–4610
   PubMed Web of Science ®Google Scholar
• Eggert A, Grotzer M A, Zuzak T J, Wiewrodt B R, Ikegaki N, Brodeur G M. Resistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Med Pediatr Oncol 2000; 35: 603–607
   PubMedGoogle Scholar
• Shiiki K, Yoshikawa H, Kinoshita H, Takeda M, Ueno A, Nakajima Y, et al. Potential mechanisms of resistance to TRAIL/Apo2L-induced apoptosis in human promyelocytic leukemia HL-60 cells during granulocytic differentiation. Cell Death Differ 2000; 7: 939–946
   PubMed Web of Science ®Google Scholar
• Griffith T S, Chin W A, Jackson G C, Lynch D H, Kubin M Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998; 161: 2833–2840
   PubMed Web of Science ®Google Scholar
• Zhang X D, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999; 59: 2747–2753
   PubMed Web of Science ®Google Scholar
• MacFarlane M. TRAIL-induced signalling and apoptosis (review). Toxicol Lett 2003; 139: 89–97
   PubMed Web of Science ®Google Scholar
• Ray S, Bucur O, Almasan A. Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis 2005; 10: 1411–1418
   PubMed Web of Science ®Google Scholar
• Kim E H, Kim H S, Kim S U, Noh E J, Lee J S, Choi K S. Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene 2005; 24: 6877–6889
   PubMed Web of Science ®Google Scholar
• Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer (review). Cancer Gene Ther 2005; 12: 228–237
   PubMed Web of Science ®Google Scholar
• Han J, Goldstein L A, Gastman B R, Rabinovitz A, Wang G Q, Fang B, et al. Differential involvement of Bax and Bak in TRAIL-mediated apoptosis of leukemic T cells. Leukemia 2004; 18: 1671–1680
   PubMed Web of Science ®Google Scholar
• Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001; 7: 680–686
   PubMed Web of Science ®Google Scholar
• Cuello M, Coats A O, Darko I, Ettenberg S A, Gardner G J, Nau M M, et al. N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines. Cell Death Differ 2004; 11: 527–541
   PubMed Web of Science ®Google Scholar
• Nagy L, Thomazy V A, Shipley G L, Fesus L, Lamph W, Heyman R A, et al. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol Cell Biol 1995; 15: 3540–3551
   PubMed Web of Science ®Google Scholar
• Cohen M H, Hirschfeld S, Flamm Honig S, Ibrahim A, Johnson J R, O'Leary J J, et al. Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist 2001; 6: 4–11
   PubMed Web of Science ®Google Scholar
• Talpur R, Ward S, Apisarnthanarax N, Breuer-Mcham J, Duvic M. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002; 47: 672–684
   PubMed Web of Science ®Google Scholar
• Krathen R A, Ward S, Duvic M. Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology 2003; 206: 142–147
   PubMed Web of Science ®Google Scholar
• Duvic M, Hymes K, Heald P, Breneman D, Martin A G, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456–2471
   PubMed Web of Science ®Google Scholar
• Rigas J R, Dragnev K H. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene (review). Oncologist 2005; 10: 22–33
   PubMed Web of Science ®Google Scholar
• Morrow P K, Kim E S. New biological agents in the treatment of advanced non-small cell lung cancer (review). Semin Res Crit Care Med 2005; 26: 323–332
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Ward J L, Deeg H J. Chelerythrin activates caspase-8, downregulates FLIP long and short, and overcomes resistance to tumour necrosis factor-related apoptosis-inducing ligand in KG1a cells. Br J Haematol 2003; 122: 489–497
   PubMed Web of Science ®Google Scholar
• Benesch M, Platzbecker U, Ward J, Deeg H J, Leisenring W. Expression of FLIPlong and FLIPshort in bone marrow mononuclear and CD34+ cells in patients with myelodysplastic syndrome: correlation with apoptosis. Leukemia 2003; 17: 2460–2466
   PubMed Web of Science ®Google Scholar
• Kerbauy D MB, Lesnikov V, Abbasi N, Seal S, Scott B, Deeg H J. NF-κB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood 2005; 106: 3917–3925
   PubMed Web of Science ®Google Scholar
• Gottlieb R A, Adachi S. Nitrogen cavitation for cell disruption to obtain mitochondria from cultured cells. Methods Enzymol 2000; 322: 213–221
   PubMed Web of Science ®Google Scholar
• Zang D Y, Goodwin R G, Loken M R, Bryant E, Deeg H J. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood 2001; 98: 3058–3065
   PubMed Web of Science ®Google Scholar
• Sepulveda J C, Moreno Manzano V, Alique M, Reyes P, Calvino M, Perez de Hornedo J, et al. All-trans retinoic acid induces apoptosis in human mesangial cells: involvement of stress activated p38 kinase [Spanish]. Nefrologia 2005; 25: 131–136, 138, 140
   PubMed Web of Science ®Google Scholar
• Konta T, Xu Q, Furusu A, Nakayama K, Kitamura M. Selective roles of retinoic acid receptor and retinoid x receptor in the suppression of apoptosis by all-trans-retinoic acid. J Biol Chem 2001; 276: 12697–12701
   PubMed Web of Science ®Google Scholar
• Riccioni R, Pasquini L, Mariani G, Saulle E, Rossini A, Diverio D, et al. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 2005; 90: 612–624
   PubMed Web of Science ®Google Scholar
• Secchiero P, Vaccarezza M, Gonelli A, Zauli G. TNF-related apoptosis-inducing ligand (TRAIL): a potential candidate for combined treatment of hematological malignancies (review). Curr Pharm Des 2004; 10: 3673–3681
   PubMed Web of Science ®Google Scholar
• Safi R, Kovacic A, Gaillard S, Murata Y, Simpson E R, McDonnell D P, et al. Coactivation of liver receptor homologue-1 by peroxisome proliferator-activated receptor gamma coactivator-1alpha on aromatase promoter II and its inhibition by activated retinoid X receptor suggest a novel target for breast-specific antiestrogen therapy. Cancer Res 2005; 65: 11762–11770
   PubMed Web of Science ®Google Scholar
• Fesik S W. Promoting apoptosis as a strategy for cancer drug discovery (review). Nat Rev Cancer 2005; 5: 876–885
   PubMed Web of Science ®Google Scholar
• Wajant H, Pfizenmaier K, Scheurich P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy (review). Apoptosis 2002; 7: 449–459
   PubMed Web of Science ®Google Scholar
• Yagita H, Takeda K, Hayakawa Y, Smyth M J, Okumura K. TRAIL and its receptors as targets for cancer therapy (review). Cancer Sci 2004; 95: 777–783
   PubMed Web of Science ®Google Scholar
• Hawkins C J. TRAIL and malignant glioma (review). Vitamins & Hormones 2004; 67: 427–452
   PubMed Web of Science ®Google Scholar
• Wu X X, Ogawa O, Kakehi Y. TRAIL and chemotherapeutic drugs in cancer therapy (review). Vitamins & Hormones 2004; 67: 365–383
   PubMed Web of Science ®Google Scholar
• Kaufmann S H, Steensma D P. On the TRAIL of a new therapy for leukemia (review). Leukemia 2005; 19: 2195–2202
   PubMed Web of Science ®Google Scholar
• Rizvi N A, Marshall J L, Dahut W, Ness E, Truglia J A, Loewen G, et al. A Phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res 1999; 5: 1658–1664
   PubMed Web of Science ®Google Scholar